{"id":"https://openalex.org/W2013000677","doi":"https://doi.org/10.1016/j.ejca.2014.01.012","title":"Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas","display_name":"Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas","publication_year":2014,"publication_date":"2014-02-07","ids":{"openalex":"https://openalex.org/W2013000677","doi":"https://doi.org/10.1016/j.ejca.2014.01.012","mag":"2013000677","pmid":"https://pubmed.ncbi.nlm.nih.gov/24512981"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejca.2014.01.012","doi":"https://doi.org/10.1016/j.ejca.2014.01.012","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2014.01.012","pdf_url":"http://www.ejcancer.com/article/S095980491400046X/pdf","source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.ejcancer.com/article/S095980491400046X/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042202815","display_name":"Jean\u2010Yves Blay","orcid":"https://orcid.org/0000-0001-7190-120X","observed_orcids":["https://orcid.org/0000-0001-7190-120X"]},"institutions":[{"id":"https://openalex.org/I4210105738","display_name":"Centre L\u00e9on B\u00e9rard","ror":"https://ror.org/01cmnjq37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210105738"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Jean-Yves Blay","raw_affiliation_strings":["Centre L\u00e9on B\u00e9rard, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr","Centre Leon Berard"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre L\u00e9on B\u00e9rard, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr","institution_ids":["https://openalex.org/I4210105738"]},{"raw_affiliation_string":"Centre Leon Berard","institution_ids":["https://openalex.org/I4210105738"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102948909","display_name":"Michael Gordon Leahy","orcid":"https://orcid.org/0000-0002-9936-0537","observed_orcids":["https://orcid.org/0000-0002-9936-0537"]},"institutions":[{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michael G. Leahy","raw_affiliation_strings":["The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073741289","display_name":"Binh Bui Nguyen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134409","display_name":"Institut Bergoni\u00e9","ror":"https://ror.org/02yw1f353","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210134409"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Binh Bui Nguyen","raw_affiliation_strings":["Institut Bergonie, Bordeaux, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Bergonie, Bordeaux, France","institution_ids":["https://openalex.org/I4210134409"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001104743","display_name":"SHREYASKUMAR R. PATEL","orcid":"https://orcid.org/0000-0002-0026-2348","observed_orcids":["https://orcid.org/0000-0002-0026-2348"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shreyaskumar R. Patel","raw_affiliation_strings":["University of Texas M. D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M. D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046601855","display_name":"Peter Hohenberger","orcid":"https://orcid.org/0000-0001-5359-5923","observed_orcids":["https://orcid.org/0000-0001-5359-5923"]},"institutions":[{"id":"https://openalex.org/I4210156450","display_name":"University Medical Centre Mannheim","ror":"https://ror.org/05sxbyd35","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210156450"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Peter Hohenberger","raw_affiliation_strings":["Universit\u00e4tsklinikum Mannheim, Mannheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e4tsklinikum Mannheim, Mannheim, Germany","institution_ids":["https://openalex.org/I4210156450"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100766578","display_name":"Armando Santoro","orcid":"https://orcid.org/0000-0003-1709-9492","observed_orcids":["https://orcid.org/0000-0003-1709-9492"]},"institutions":[{"id":"https://openalex.org/I4210163047","display_name":"IRCCS Humanitas Research Hospital","ror":"https://ror.org/05d538656","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210163047"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Armando Santoro","raw_affiliation_strings":["Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy","institution_ids":["https://openalex.org/I4210163047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089966140","display_name":"Arthur P. Staddon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800191209","display_name":"Pennsylvania Hospital","ror":"https://ror.org/03mvdc478","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800191209","https://openalex.org/I4210143392"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arthur P. Staddon","raw_affiliation_strings":["Joan Karnell Cancer Center, Pennsylvania Hospital, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Joan Karnell Cancer Center, Pennsylvania Hospital, PA, USA","institution_ids":["https://openalex.org/I2800191209"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052242950","display_name":"Nicolas Penel","orcid":"https://orcid.org/0000-0001-5243-1548","observed_orcids":["https://orcid.org/0000-0001-5243-1548"]},"institutions":[{"id":"https://openalex.org/I4210131356","display_name":"Centre Oscar Lambret","ror":"https://ror.org/03xfq7a50","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210131356","https://openalex.org/I4210141925"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Nicolas Penel","raw_affiliation_strings":["Centre Oscar Lambret, Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre Oscar Lambret, Lille, France","institution_ids":["https://openalex.org/I4210131356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066286234","display_name":"Sophie Piperno-Neumann","orcid":"https://orcid.org/0000-0001-9915-2810","observed_orcids":["https://orcid.org/0000-0001-9915-2810"]},"institutions":[{"id":"https://openalex.org/I80043","display_name":"Institut Curie","ror":"https://ror.org/04t0gwh46","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I80043"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Sophie Piperno-Neumann","raw_affiliation_strings":["Institut Curie, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Curie, Paris, France","institution_ids":["https://openalex.org/I80043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027630636","display_name":"Andrew Eugene Hendifar","orcid":"https://orcid.org/0000-0002-2079-9177","observed_orcids":["https://orcid.org/0000-0002-2079-9177"]},"institutions":[{"id":"https://openalex.org/I4210104185","display_name":"Sarcoma Oncology Center","ror":"https://ror.org/01k15w004","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210104185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Hendifar","raw_affiliation_strings":["Sarcoma Oncology Center, Santa Monica, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarcoma Oncology Center, Santa Monica, CA, USA","institution_ids":["https://openalex.org/I4210104185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007422243","display_name":"Pilar Lardelli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pilar Lardelli","raw_affiliation_strings":["PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain","institution_ids":["https://openalex.org/I4210116403"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Antonio Nieto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Antonio Nieto","raw_affiliation_strings":["PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain","institution_ids":["https://openalex.org/I4210116403"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048398150","display_name":"Vicente Alfaro","orcid":"https://orcid.org/0000-0002-0150-2390","observed_orcids":["https://orcid.org/0000-0002-0150-2390"]},"institutions":[{"id":"https://openalex.org/I4210116403","display_name":"PharmaMar (Spain)","ror":"https://ror.org/02h694m69","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210116403"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Vicente Alfaro","raw_affiliation_strings":["PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain","institution_ids":["https://openalex.org/I4210116403"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073906112","display_name":"Sant P. Chawla","orcid":"https://orcid.org/0000-0002-9522-6744","observed_orcids":["https://orcid.org/0000-0002-9522-6744"]},"institutions":[{"id":"https://openalex.org/I4210104185","display_name":"Sarcoma Oncology Center","ror":"https://ror.org/01k15w004","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210104185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sant P. Chawla","raw_affiliation_strings":["Sarcoma Oncology Center, Santa Monica, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarcoma Oncology Center, Santa Monica, CA, USA","institution_ids":["https://openalex.org/I4210104185"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5042202815"],"corresponding_institution_ids":["https://openalex.org/I4210105738"],"apc_list":{"value":4270,"currency":"USD","value_usd":4270},"apc_paid":{"value":4270,"currency":"USD","value_usd":4270},"fwci":10.3203,"has_fulltext":true,"cited_by_count":123,"citation_normalized_percentile":{"value":0.99084308,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"50","issue":"6","first_page":"1137","last_page":"1147"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trabectedin","display_name":"trabectedin","score":0.9850000143051147},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.921999990940094},{"id":"https://openalex.org/keywords/ifosfamide","display_name":"ifosfamide","score":0.9409999847412109},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.8100000023841858},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9919999837875366},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.7300000190734863},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7900000214576721},{"id":"https://openalex.org/keywords/chemotherapy-toxicity","display_name":"chemotherapy toxicity","score":0.382999986410141}],"concepts":[{"id":"https://openalex.org/C2780752271","wikidata":"https://www.wikidata.org/wiki/Q2637746","display_name":"Trabectedin","level":4,"score":0.9275886416435242},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7984164953231812},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6294799447059631},{"id":"https://openalex.org/C2777506904","wikidata":"https://www.wikidata.org/wiki/Q418560","display_name":"Ifosfamide","level":4,"score":0.6023914813995361},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.5791491270065308},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5245956778526306},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5236544609069824},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5169203281402588},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.501061201095581},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.4979362487792969},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4965890049934387},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4348737597465515},{"id":"https://openalex.org/C2778256501","wikidata":"https://www.wikidata.org/wiki/Q223911","display_name":"Sarcoma","level":2,"score":0.4108033776283264},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38728585839271545},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3399810791015625},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.23767098784446716},{"id":"https://openalex.org/C2778629024","wikidata":"https://www.wikidata.org/wiki/Q720020","display_name":"Soft tissue sarcoma","level":3,"score":0.20766425132751465},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.16998812556266785},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.12013977766036987},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.117338627576828},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077606","descriptor_name":"Trabectedin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004149","descriptor_name":"Dioxoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004149","descriptor_name":"Dioxoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007069","descriptor_name":"Ifosfamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007069","descriptor_name":"Ifosfamide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007970","descriptor_name":"Leukopenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D012509","descriptor_name":"Sarcoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012509","descriptor_name":"Sarcoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D014178","descriptor_name":"Translocation, Genetic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044005","descriptor_name":"Tetrahydroisoquinolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D044005","descriptor_name":"Tetrahydroisoquinolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.ejca.2014.01.012","doi":"https://doi.org/10.1016/j.ejca.2014.01.012","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2014.01.012","pdf_url":"http://www.ejcancer.com/article/S095980491400046X/pdf","source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},{"id":"pmid:24512981","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24512981","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of cancer (Oxford, England : 1990)","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:zenodo.org:84425","doi":null,"is_oa":true,"landing_page_url":"https://www.openaccessrepository.it/record/84425","pdf_url":null,"source":{"id":"https://openalex.org/S4306402478","display_name":"INFM-OAR (INFN Catania)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210116497","host_organization_name":"Istituto Nazionale di Fisica Nucleare, Sezione di Catania","host_organization_lineage":["https://openalex.org/I4210116497"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1016/j.ejca.2014.01.012","doi":"https://doi.org/10.1016/j.ejca.2014.01.012","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2014.01.012","pdf_url":"http://www.ejcancer.com/article/S095980491400046X/pdf","source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320308982","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2013000677.pdf","grobid_xml":"https://content.openalex.org/works/W2013000677.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1589920570","https://openalex.org/W1828438395","https://openalex.org/W1882650898","https://openalex.org/W2013286412","https://openalex.org/W2015116906","https://openalex.org/W2028416946","https://openalex.org/W2041792131","https://openalex.org/W2042404839","https://openalex.org/W2051992326","https://openalex.org/W2091453908","https://openalex.org/W2091601272","https://openalex.org/W2103180029","https://openalex.org/W2106926141","https://openalex.org/W2107078868","https://openalex.org/W2107318974","https://openalex.org/W2113855026","https://openalex.org/W2123302336","https://openalex.org/W2123534406","https://openalex.org/W2124271256","https://openalex.org/W2147770208","https://openalex.org/W2153205088","https://openalex.org/W2156488093","https://openalex.org/W2157598836","https://openalex.org/W2161378536","https://openalex.org/W2167805334","https://openalex.org/W2168598691","https://openalex.org/W2171302499","https://openalex.org/W2397606139"],"related_works":["https://openalex.org/W2598403839","https://openalex.org/W2117431699","https://openalex.org/W2968685586","https://openalex.org/W2013286412","https://openalex.org/W2272866359","https://openalex.org/W2906850990","https://openalex.org/W2093273708","https://openalex.org/W2165252656","https://openalex.org/W2397619801","https://openalex.org/W2518267163"],"abstract_inverted_index":{"AIM:":[0],"This":[1],"randomised":[2],"phase":[3],"III":[4],"trial":[5],"evaluated":[6],"first-line":[7,215],"trabectedin":[8,28,133,206],"versus":[9,166,181],"doxorubicin-based":[10,208],"chemotherapy":[11,209],"(DXCT)":[12],"in":[13,132,144,154,162,200,213],"patients":[14,76,129,218],"with":[15,100,103,191,219],"advanced/metastatic":[16],"translocation-related":[17,221],"sarcomas":[18],"(TRS).":[19],"METHODS:":[20],"Patients":[21],"were":[22,77,94,130],"randomly":[23],"assigned":[24],"(1:1)":[25],"to":[26,150,171],"receive":[27],"1.5mg/m2":[29],"24-h":[30],"intravenous":[31],"(i.v.)":[32],"infusion":[33],"every":[34],"3":[35],"weeks":[36],"(q3wk)":[37],"(Arm":[38,58],"A),":[39],"or":[40,46],"doxorubicin":[41,47],"75":[42],"mg/m2":[43,49],"i.v.,":[44],"q3wk,":[45],"60":[48],"i.v.":[50,56],"plus":[51],"ifosfamide":[52],"(range,":[53],"6-9":[54],"g/m2)":[55],"q3wk":[57],"B).":[59],"Progression-free":[60],"survival":[61,145],"(PFS)":[62],"by":[63,85,96],"independent":[64,97],"review":[65,88,98],"was":[66,139,159,185],"the":[67,120,201,214],"primary":[68],"efficacy":[69],"end-point.":[70],"RESULTS:":[71],"One":[72],"hundred":[73],"and":[74,126,134,198],"twenty-one":[75],"randomised;":[78],"88":[79],"of":[80,122,128,194,217],"them":[81],"had":[82],"TRS":[83],"confirmed":[84],"central":[86],"pathology":[87],"(efficacy":[89],"population).":[90],"Twenty-nine":[91],"PFS":[92,105],"events":[93],"assessed":[95],"(16":[99],"trabectedin;":[101],"13":[102],"DXCT).":[104],"showed":[106,174,210],"non-significant":[107],"difference":[108,143],"between":[109,177],"arms":[110,179],"(stratified":[111],"log":[112],"rank":[113],"test,":[114],"p=0.9573;":[115],"hazard":[116],"ratio=0.86,":[117],"p=0.6992).":[118],"At":[119],"time":[121],"this":[123],"analysis,":[124],"63.9%":[125],"58.3%":[127],"alive":[131],"DXCT":[135,163,202],"arms,":[136,190],"respectively.":[137],"There":[138],"no":[140],"statistically":[141],"significant":[142,211],"curves.":[146],"Response":[147,151],"rate":[148],"according":[149,170],"Evaluation":[152],"Criteria":[153],"Solid":[155],"Tumours":[156],"(RECIST)":[157],"v.1.0":[158],"significantly":[160],"higher":[161,192],"arm":[164],"(27.0%":[165],"5.9%),":[167],"but":[168],"response":[169],"Choi":[172],"criteria":[173],"fewer":[175],"differences":[176],"treatment":[178,216],"(45.9%":[180],"37.3%).":[182],"Safety":[183],"profile":[184],"as":[186],"expected":[187],"for":[188],"both":[189],"incidence":[193],"severe":[195],"neutropenia,":[196],"alopecia":[197],"mucositis":[199],"arm.":[203],"CONCLUSION:":[204],"Neither":[205],"nor":[207],"superiority":[212],"advanced":[220],"sarcoma.":[222]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":14},{"year":2017,"cited_by_count":17},{"year":2016,"cited_by_count":23},{"year":2015,"cited_by_count":19},{"year":2014,"cited_by_count":5}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}